FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track –– Enrolling approximately one patient per week ...

What would you do if your child woke up and physically couldn’t get out of bed or walk? This was a scary reality for one ...

Varied approaches to remote patient monitoring are in development to close care gaps between patients and rheumatologists, ...

Rheumatologists and cardiologists have long co-managed patients out of necessity and without much formal collaboration or ...

After IRB approval, members of The Myositis Association (~4000 individuals with DM) were invited to complete the online survey (eligibility criteria: 18 – 75 years of age, self-reported DM diagnosis, ...

AstraZeneca's IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

The following is a summary of “Ocular features of VEXAS syndrome: a systematic review and meta-analysis,” published in the ...

Checkpoint Therapeutics, Inc. ("Checkpoint”) (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company, ...

Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications ...

Widespread chronic pain in patients with hypermobility spectrum disorder or hypermobile Ehlers-Danlos syndrome significantly affected daily activities.

Rheumatoid arthritis (RA) and lupus are sometimes confused early on because they share certain symptoms. They’re both autoimmune diseases that affect the joints. An autoimmune disease occurs ...

Checkpoint Therapeutics, Inc. ("Checkpoint") (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company, today announced financial ...